184 related articles for article (PubMed ID: 30377587)
1. Adjunctive perampanel for glioma-associated epilepsy.
Dunn-Pirio AM; Woodring S; Lipp E; Herndon JE; Healy P; Weant M; Randazzo D; Desjardins A; Friedman HS; Peters KB
Epilepsy Behav Case Rep; 2018; 10():114-117. PubMed ID: 30377587
[TBL] [Abstract][Full Text] [Related]
2. Perampanel: What is its Place in the Management of Partial Onset Epilepsy?
Ledingham DR; Patsalos PN
Neurol Ther; 2013 Dec; 2(1-2):13-24. PubMed ID: 26000213
[TBL] [Abstract][Full Text] [Related]
3. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
[TBL] [Abstract][Full Text] [Related]
4. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.
Steinhoff BJ
Ther Adv Neurol Disord; 2015 May; 8(3):137-47. PubMed ID: 25941541
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies.
Kwan P; Mintzer S; Laurenza A; Patten A; Cartwright K
Epilepsy Behav Case Rep; 2018; 9():1-5. PubMed ID: 29707476
[TBL] [Abstract][Full Text] [Related]
6. Perampanel: A Review in Drug-Resistant Epilepsy.
Frampton JE
Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
[TBL] [Abstract][Full Text] [Related]
7. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
8. Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel.
Izumoto S; Miyauchi M; Tasaki T; Okuda T; Nakagawa N; Nakano N; Kato A; Fujita M
Anticancer Res; 2018 Jul; 38(7):4361-4366. PubMed ID: 29970574
[TBL] [Abstract][Full Text] [Related]
9. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures.
Besag FM; Patsalos PN
Neuropsychiatr Dis Treat; 2016; 12():1215-20. PubMed ID: 27274257
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
14. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.
Zaccara G; Giovannelli F; Cincotta M; Iudice A
Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.
Ettinger AB; LoPresti A; Yang H; Williams B; Zhou S; Fain R; Laurenza A
Epilepsia; 2015 Aug; 56(8):1252-63. PubMed ID: 26140524
[TBL] [Abstract][Full Text] [Related]
17. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
El Desoky ES
Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
[TBL] [Abstract][Full Text] [Related]
18. An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients.
Dozières-Puyravel B; Auvin S
Neuropsychiatr Dis Treat; 2019; 15():2789-2798. PubMed ID: 31576134
[TBL] [Abstract][Full Text] [Related]
19. Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies.
Lim GY; Chen CL; Chan Wei Shih D
Child Neurol Open; 2021; 8():2329048X211055335. PubMed ID: 34820471
[TBL] [Abstract][Full Text] [Related]
20. Novel treatment options for epilepsy: focus on perampanel.
Franco V; Crema F; Iudice A; Zaccara G; Grillo E
Pharmacol Res; 2013 Apr; 70(1):35-40. PubMed ID: 23287426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
